MedTrace Logo

The Effect of Symbiotic Beverage Consumption on Lipid Profile

NCT06893991 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-25

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether the synbiotic beverage "Daygurt" can improve lipid profiles, blood sugar levels, blood pressure, and body weight in individuals diagnosed with dyslipidemia. The main questions it aims to answer are:

Does "Daygurt" significantly reduce total cholesterol and LDL levels compared to nutrition counseling alone? Does "Daygurt" increase HDL levels and reduce triglycerides more effectively than nutrition counseling? Does "Daygurt" lead to greater improvements in fasting blood sugar, blood pressure, and body weight compared to nutrition counseling?

The intervention group (receiving "Daygurt" plus nutrition counseling) will be compared to the comparison group (receiving nutrition counseling without "Daygurt") to see if "Daygurt" provides additional benefits beyond standard dietary advice.

Participants will be divided into 2 groups:

Intervention group: Consume "Daygurt" daily for 8 weeks. Comparison group: Receive nutrition counseling sessions focused on managing dyslipidemia but will not consume "Daygurt."

Both groups will undergo health parameter measurements before and after the intervention, including:

Total cholesterol, LDL, HDL, and triglyceride levels. Fasting blood sugar. Blood pressure. Body mass index (BMI).

Conditions

  • Lipid Profile
  • Fasting Blood Sugar Above Normal
  • Body Mass Index

Interventions

DIETARY_SUPPLEMENT

SYMBIONIC

Provision of 100 ml symbiotic beverages "daygurt" per day for 6 weeks, plus standard dietary advice for dyslipidemia

BEHAVIORAL

Dietary advice

Participants get standard dietary advice for dyslipidemia

Sponsors & Collaborators

  • Politeknik Kesehatan Kemenkes Padang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-27
Primary Completion
2025-06-15
Completion
2025-10-15

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06893991 on ClinicalTrials.gov